Navigation Links
Oncothyreon's PX-478 is effective in preclinical model of human lung cancer
Date:2/25/2008

BELLEVUE, WA, Feb. 25 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq - ONTY) (TSX - ONY) (the "Company") today announced the presentation of data demonstrating the effectiveness of PX-478 in a preclinical model of human lung cancer at the 8th Annual Targeted Therapies of the Treatment of Lung Cancer meeting of the International Association for the Study of Lung Cancer in Santa Monica, California. The data were presented on February 22, 2008, by Jorg J. Jacoby, Ph.D., Instructor, University of Texas M.D. Anderson Cancer Center, Houston. Oncothyreon's PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a Phase 1 trial in patients with advanced metastatic cancer and lymphoma.

The study employed a model of lung cancer in mice, which closely mimics the disease in humans. Treatment with oral PX-478 for five days resulted in significant inhibition of tumor growth, marked reduction in lymph nodes metastases, decreased volume of pleural effusions, and significantly improved survival. PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.

"These data suggest that antagonism of HIF-1 alpha with PX-478 significantly inhibits the growth and spread of lung cancers expressing HI-1 alpha and will prove valuable in planning clinical trials of this novel agent," said Roy Herbst, M.D., Professor, Thoracic/Head & Neck Medical Oncology, M.D. Anderson Cancer Center, and senior author of the current study. "We look forward to conducting further studies of PX-478 in combination with other agents used in the treatment of these diseases, and to participating in future clinical trials of this highly promising drug candidate."

Enrollment is ongoing in the Phase 1 dose escalation trial of PX-478 in patients with advanced metastatic cancer and lymphoma. Clinical data from this trial are expected in the second half of 2008.

About PX-478

PX-478 is a n
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Phase III Trial Finds Pharmaxis Bronchitol Effective
2. New nanoparticle vaccine is more effective but less expensive
3. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
4. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
5. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
6. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
7. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
8. DNA sensors found to be an effective artificial nose
9. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
10. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
11. Genmab Announces Encouraging Preclinical Data for ofatumumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Clinverse, Inc. , a ... trials, today announced it will be exhibiting and ... in Boston, June 24-26, 2013. Clinverse’s eClinical ... fully configurable, cloud-based clinical financial lifecycle system. , ... Clinverse’s eClinical Commerce Network, automates site contract set-up ...
(Date:6/19/2013)... June 19, 2013 Bayer CropScience will ... Bayer Bee Care Community Leadership Award. The award will ... Congressional Reception in Washington, D.C., an event where supporters ... the world’s food supply. , The Bayer Bee ... the power of the honey bee colony to benefit ...
(Date:6/19/2013)... Canada (PRWEB) June 19, 2013 ... trial business can potentially be worth up to ... this opportunity, the Indian government is taking serious ... trials the process. , This presentation will examine:, ... trial regulations ,     Immediate and long term ...
(Date:6/18/2013)... June 18, 2013 Tabletop SEMs are ... SEMs but have limited performance and capability such as ... size SEMs would normally provide better imaging performance and ... operate and have a higher cost of maintenance. ... gap between these two types of SEM product, offering ...
Breaking Biology Technology:Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3
... 19, 2011 , , • ... MS drug with neuroprotective effects that does not cause,immunosuppression. ... the first,to be administered orally, whereas the few treatments ... significant side effects. • NeuroAdvan, the ...
... Mosquitoes die soon after a blood meal if certain ... at the University of Arizona has discovered. The ... the worldwide effort to curb mosquito-borne diseases like dengue ... blocked a cellular process known as vesicle transport, on ...
... dots made from cadmium and selenium degrade in soil, ... a University at Buffalo study has found. The ... Science and Technology , demonstrates the importance of learning ... -- interact with the environment after disposal, said Diana ...
Cached Biology Technology:Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 2Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 4Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 5Making blood-sucking deadly for mosquitoes 2Making blood-sucking deadly for mosquitoes 3Making blood-sucking deadly for mosquitoes 4Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 2Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 3
(Date:6/18/2013)... University of Calgary,s Faculty of Medicine have discovered a ... harmful bacteria. Platelets, a component of blood typically associated ... bacteria, and upon detection, seal it off from the ... in Nature Immunology this week, provide the ... "The science community has known that platelets do participate ...
(Date:6/18/2013)... Research Council, Laboratory of Molecular Biology, has been ... Young Investigator Award. Torrent is being recognized for ... algorithm to predict antimicrobial regions in proteins. Luis ... now applying this algorithm to interrogate full genomes ... with very appealing results." , Torrent obtained ...
(Date:6/18/2013)... It is estimated that between 5% and 10% of ... is to say that these tumours are attributable to ... BRCA1 or BRCA2. In patients with these mutations, PARP ... encouraging results that make them a new option for ... the latest studies indicate that a fraction of these ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2The American Society for Microbiology honors Marc Torrent 2An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... blocks the brain’s ability to strengthen connections at inhibitory synapses, ... The findings, uncovered in the laboratory of Brown scientist Julie ... brain. The research also supports a provocative new theory of ... "We’ve added a new piece to the puzzle of how ...
... three sexually active older adults infected with HIV has unprotected ... survey of 260 HIV-positive older adults found that of those ... a relationship. , AIDs cases among the over-50 crowd reached ... and Prevention, they will account for half of all HIV/AIDS ...
... Beucken and John Jansen have given body implants a DNA ... of the surrounding tissue and less immune responses. The older ... placing such parts yielded advantages, but also disadvantages such as ... easier and more reliable to use implants and has already ...
Cached Biology News:Morphine makes lasting -- and surprising -- change in the brain 21/3 of sexually active older adults with HIV/AIDs has unprotected sex 2DNA layer reduces risk of reserve parts being rejected 2
... sulfate-free, powder containing carbohydrate and citrate ... Definition: One unit will convert 1.0 ... to D -glucose 6-phosphate per ... C. Chem comp: Protein ...
... Vector is specifically designed to target and ... Saccharomyces cerevisiae. Displayed proteins can be analyzed ... or putative ligands. pYD1 uses the a-agglutinin ... domains Aga1 and Aga2 to display recombinant ...
... Polyclonal Antibody against Aph-1a (Aph-1aL,S Loop ... gamma secretase is a multiprotein complex ... Pen-2; all four proteins are necessary ... secretase complex catalyzes cleavage of a ...
TGase3 (S-20)...
Biology Products: